(Q34747405)

English

Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM). (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

1 reference

based on heuristic

inferred from title

author name string

A Josting

1

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

I Kàtay

2

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

U Rueffer

3

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

S Winter

4

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

H Tesch

5

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

A Engert

6

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

V Diehl

7

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

P D Wickramanayake

8

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

publication date

1 March 1998

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

289-295

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008283909959

7 January 2021

based on heuristic

inferred from DOI database lookup

Is there an effective salvage therapy for advanced Hodgkin's disease?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008283909959

7 January 2021

based on heuristic

inferred from DOI database lookup

The second chance for advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008283909959

7 January 2021

based on heuristic

inferred from DOI database lookup

Salvage therapy of advanced Hodgkin's disease. Critical appraisal of curative potential

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008283909959

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008283909959

7 January 2021

based on heuristic

inferred from DOI database lookup

High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008283909959

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008283909959

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous bone marrow transplantation for patients with relapsed hodgkin's disease

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008283909959

7 January 2021

based on heuristic

inferred from DOI database lookup

Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008283909959

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008283909959

7 January 2021

based on heuristic

inferred from DOI database lookup

One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008283909959

7 January 2021

based on heuristic

inferred from DOI database lookup

Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008283909959

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008283909959

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008283909959

7 January 2021

based on heuristic

inferred from DOI database lookup

MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008283909959

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008283909959

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of refractory and relapsed Hodgkin's disease: intensive chemotherapy and autologous bone marrow or peripheral blood stem cell support

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008283909959

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008283909959

7 January 2021

based on heuristic

inferred from DOI database lookup

Stepwise progress in the treatment of disseminated cancers

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008283909959

7 January 2021

based on heuristic

inferred from DOI database lookup

Single cell origin of multilineage colonies in culture. Evidence that differentiation of multipotent progenitors and restriction of proliferative potential of monopotent progenitors are stochastic processes

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008283909959

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1008283909959

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34747405&oldid=1448056901"